Recognizing Risk and the Broader Health Impact in MASH

Panelists discuss how multiple patient factors—including obesity severity, metabolic syndrome, and comorbidities like diabetes and kidney disease—predict MASH risk. They highlight that identifying high-risk profiles allows clinicians to tailor care and prevent progression to fibrosis or cirrhosis.

The panel expands on how interconnected diseases compound one another, noting that MASH often coexists with cardiovascular and renal conditions that demand coordinated management. They stress that failing to address liver health holistically can undermine broader cardiometabolic outcomes.

The conversation also explores the economic dimension, revealing that MASH contributes substantially to healthcare costs. Panelists advocate for improved awareness, earlier intervention, and alignment across payers and clinicians to mitigate systemic and financial burden.